Efmoroctocog alfa, Recombinant factor VIII, Fc tagged

Specification

• Cat#: THP-0065
• Product Name: Efmoroctocog alfa, Recombinant factor VIII, Fc tagged
• Cas No: 1270012-79-7
• Description: The product is a fully recombinant factor VIII-Fc fusion protein (rFVIIIFc) with an extended half-life compared with conventional factor VIII (FVIII) preparations, including recombinant FVIII (rFVIII) products such as Moroctocog alfa. Factor VIII is a blood coagulant factor involved in the intrinsic pathway to form fibrin, or a blood clot. The product is a first commercially available rFVIII-Fc fusion protein (rFVIIIFc) where the conjugated molecule of rFVIII to polyethylene glycol is covalently fused to the dimeric Fc domain of human immunoglobulin G1, a long-lived plasma protein. The B domain of factor VIII is deleted.
• Sequences: Not Available
• Species: Human
• Molecular Weight: 220000.0 Da (Apparent, B-domain deleted)
• Purity: >99% by SDS-Page and HPLC analysis
• Formula: C9736H14863N2591O2855S78
• Endotoxin: <0.001 EU per 1 μg of the protein by the LAL method
• Biological Activity: 1500U/3ml
• Application: Indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).

Pharmaceutical Information

• Pharmaceutical Application: Efmoroctocog alfa
• Targets: Target 1. von Willebrand factor